A. Alaeus

发表

Subtype‐specific problems with quantification of plasma HIV‐1 RNA

J. Albert, A. Sönnerborg, K. Lidman, 1997, AIDS.

Assay of plasma samples representing different HIV-1 genetic subtypes: an evaluation of new versions of the amplicor HIV-1 monitor assay.

J. Albert, J. Spadoro, S. Herman, 1999, AIDS research and human retroviruses.

Elevated Numbers of FcγRIIIA+ (CD16+) Effector CD8 T Cells with NK Cell-Like Function in Chronic Hepatitis C Virus Infection1

H. Ljunggren, O. Weiland, Veronica D. Gonzalez, 2008, The Journal of Immunology.

Infection Function in Chronic Hepatitis C Virus Effector CD 8 T Cells with NK Cell-Like ) + ( CD 16 + RIIIA γ Elevated Numbers of Fc

H. Ljunggren, O. Weiland, Veronica D. Gonzalez, 2008 .

Effects of potent antiretroviral therapy on the immune activation marker soluble CD27 in patients infected with HIV‐1 subtypes A–D

F. Chiodi, A. Lindström, A. De Milito, 2004, Journal of medical virology.

Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.

Veronica D. Gonzalez, J. Michaëlsson, K. Falconer, 2008, Clinical Immunology.

IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV

K. Hellstrand, K. Falconer, N. Weis, 2010, Scandinavian journal of infectious diseases.

Expansion of Functionally Skewed CD56-Negative NK Cells in Chronic Hepatitis C Virus Infection: Correlation with Outcome of Pegylated IFN-α and Ribavirin Treatment1

H. Ljunggren, O. Weiland, Veronica D. Gonzalez, 2009, The Journal of Immunology.

and Ribavirin Treatment a of Pegylated IFN-C Virus Infection: Correlation with Outcome Hepatitis CD56-Negative NK Cells in Chronic Expansion of Functionally Skewed

O. Weiland, Veronica D. Gonzalez, K. Blom, 2009 .

Most HIV‐1 genetic subtypes have entered Sweden

T. Leitner, J. Albert, K. Lidman, 1997, AIDS.

High Levels of Chronic Immune Activation in the T-Cell Compartments of Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1 and on Highly Active Antiretroviral Therapy Are Reverted by Alpha Interferon and Ribavirin Treatment

B. Mørn, K. Blom, K. Falconer, 2009, Journal of Virology.

Chronic Hepatitis C: Updated Swedish Consensus

O. Weiland, I. Uhnoo, B. Fischler, 2003, Scandinavian journal of infectious diseases.

Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.

J. Albert, S. Cox, S. Palmer, 1998, AIDS research and human retroviruses.

Vertical transmission of hepatitis C virus infection.

M. Forsgren, A. Németh, B. Fischler, 1996, Scandinavian journal of infectious diseases.

Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles.

B. Ensoli, B. Wahrén, S. Buttò, 2008, Vaccine.

Significance of HIV-1 Genetic Subtypes

A. Alaeus, Annette Alaeus, 2000, Scandinavian journal of infectious diseases.

Daily Sampling of an HIV-1 Patient with Slowly Progressing Disease Displays Persistence of Multiple env Subpopulations Consistent with Neutrality

R. Gutenkunst, T. Leitner, J. Albert, 2011, PloS one.

Differences in chemokine coreceptor usage between genetic subtypes of HIV-1.

J. Albert, E. Fenyö, D. Littman, 1998, Virology.

Spontaneous HCV clearance in HCV/HIV-1 coinfection associated with normalized CD4 counts, low level of chronic immune activation and high level of T cell function.

K. Falconer, O. Reichard, A. Alaeus, 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HCV/HIV co-infection at a large HIV outpatient clinic in Sweden: Feasibility and results of hepatitis C treatment

K. Falconer, O. Reichard, A. Alaeus, 2009, Scandinavian journal of infectious diseases.

Branhamella catarrhalis septicemia in an immunocompetent adult.

A. Alaeus, G. Stiernstedt, Göuran Stiernstedt, 1991, Scandinavian journal of infectious diseases.

Characterization of subtype A HIV-1 from Africa by full genome sequencing.

J. Carr, M. Salminen, E. Sanders-Buell, 1999, AIDS.

Yet another subtype of HIV type 1?

T. Leitner, J. Albert, K. Lidman, 1995, AIDS research and human retroviruses.

Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy.

F. Granath, S. Lindbäck, K. Lidman, 2005, AIDS research and human retroviruses.

J. Giesecke, J. Albert, A. Björkman, 1999, AIDS.

Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE.

T. Leitner, I. Maljkovic, Karin Wilbe, 2003, AIDS research and human retroviruses.

Interferon‐α2b treatment in hepatitis B carriers. Effect on hepatitis B virus DNA levels in children infected with different genotypes

P. Sangfelt, O. Reichard, H. Norder, 1997, Acta paediatrica.

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden

A. Neubauer, B. Heeg, P. Thuresson, 2011, Scandinavian journal of infectious diseases.

Therapeutic immunization for HIV

B. Wahrén, B. Hejdeman, K. Lidman, 2006, Springer Seminars in Immunopathology.

Cross-Reactive T-Helper Responses in Patients Infected with Different Subtypes of Human Immunodeficiency Virus Type 1

J. Albert, E. Sandström, B. Wahrén, 2000, Journal of virology.

Expansion of Functionally Skewed CD56-Negative NK Cells in Chronic Hepatitis C Virus Infection: Correlation with Outcome of Pegylated IFN-α and Ribavirin Treatment1

H. Ljunggren, O. Weiland, N. Björkström, 2009, The Journal of Immunology.

Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin.

J. Michaëlsson, K. Falconer, M. Moll, 2008, Clinical immunology.

Ribavirin Treatment α of Pegylated IFN-C Virus Infection : Correlation with Outcome HepatitisCD 56-Negative NK Cells in Chronic Expansion of Functionally Skewed

O. Weiland, K. Blom, K. Falconer, 2009 .

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden

A. Neubauer, B. Heeg, P. Thuresson, 2011, Scandinavian journal of infectious diseases.